What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment
作者： Joyce F. Liu , Ursula A. Matulonis
DOI: 10.1007/S11912-016-0515-Z
关键词: Veliparib 、 Medicine 、 Oncology 、 Rucaparib 、 Olaparib 、 Chemotherapy 、 Maintenance therapy 、 PARP inhibitor 、 Ovarian cancer 、 Poly ADP ribose polymerase 、 Internal medicine
摘要: … cancer activity has led to the European Medicines Agency (EMA) approval of the PARP inhibitor (PARPi… -deficient and triple-negative breast cancer, which suggested that duration of …
springer.com
sci-hub.se 参考文章(49)
Clare L. Scott, Elizabeth M. Swisher, Scott H. Kaufmann, Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development Journal of Clinical Oncology. ,vol. 33, pp. 1397- 1406 ,(2015) , 10.1200/JCO.2014.58.8848
Jean-Christophe Amé, Catherine Spenlehauer, Gilbert de Murcia, The PARP superfamily. BioEssays. ,vol. 26, pp. 882- 893 ,(2004) , 10.1002/BIES.20085
V Abkevich, K M Timms, B T Hennessy, J Potter, M S Carey, L A Meyer, K Smith-McCune, R Broaddus, K H Lu, J Chen, T V Tran, D Williams, D Iliev, S Jammulapati, L M FitzGerald, T Krivak, J A DeLoia, A Gutin, G B Mills, J S Lanchbury, Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer British Journal of Cancer. ,vol. 107, pp. 1776- 1782 ,(2012) , 10.1038/BJC.2012.451
Robert L. Coleman, Michael W. Sill, Katherine Bell-McGuinn, Carol Aghajanian, Heidi J. Gray, Krishnansu S. Tewari, Steven C. Rubin, Thomas J. Rutherford, John K. Chan, Alice Chen, Elizabeth M. Swisher, A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – an NRG Oncology/Gynecologic Oncology Group study Gynecologic Oncology. ,vol. 137, pp. 386- 391 ,(2013) , 10.1016/J.YGYNO.2015.03.042
Junko Murai, Shar-yin N. Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H. Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier, Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors Cancer Research. ,vol. 72, pp. 5588- 5599 ,(2012) , 10.1158/0008-5472.CAN-12-2753
Kathryn P. Pennington, Tom Walsh, Maria I. Harrell, Ming K. Lee, Christopher C. Pennil, Mara H. Rendi, Anne Thornton, Barbara M. Norquist, Silvia Casadei, Alexander S. Nord, Kathy J. Agnew, Colin C. Pritchard, Sheena Scroggins, Rochelle L. Garcia, Mary-Claire King, Elizabeth M. Swisher, Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas Clinical Cancer Research. ,vol. 20, pp. 764- 775 ,(2014) , 10.1158/1078-0432.CCR-13-2287
Tomoe Higuchi, Dallas B. Flies, Nicole A. Marjon, Gina Mantia-Smaldone, Lukas Ronner, Phyllis A. Gimotty, Sarah F. Adams, CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer Cancer immunology research. ,vol. 3, pp. 1257- 1268 ,(2015) , 10.1158/2326-6066.CIR-15-0044
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas Loman, Karen Lu, Rita K Schmutzler, Ursula Matulonis, Mark Wickens, Andrew Tutt, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial The Lancet. ,vol. 376, pp. 245- 251 ,(2010) , 10.1016/S0140-6736(10)60893-8
H. Hirte, S. Lheureux, G.F. Fleming, A. Sugimoto, R. Morgan, J. Biagi, L. Wang, S. McGill, S.P. Ivy, A.M. Oza, A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia. Gynecologic Oncology. ,vol. 138, pp. 55- 61 ,(2015) , 10.1016/J.YGYNO.2015.04.009
Ranjit S. Bindra, Shannon L. Gibson, Alice Meng, Ulrica Westermark, Maria Jasin, Andrew J. Pierce, Robert G. Bristow, Marie K. Classon, Peter M. Glazer, Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Research. ,vol. 65, pp. 11597- 11604 ,(2005) , 10.1158/0008-5472.CAN-05-2119